Work

MBX-500 Is Effective for Treatment of Clostridium difficile Infection in Gnotobiotic Piglets

Year: 2013

Type: article

Abstract: The novel antibiotic MBX-500, dosed at 100, 200, or 400 mg/kg twice daily for 7 days, was evaluated for the treatment of Clostridium difficile infection (CDI) in the gnotobiotic pig model. MBX-500 increased survival at all doses and at high doses improved clinical signs and reduced lesion severity, similar to vancomycin. Our results show that MBX-500 is an effective antibiotic for the treatment of diarrhea associated with CDI and prevents severe systemic disease.

Source: Antimicrobial Agents and Chemotherapy

DOI: 10.1128/aac.00304-13

Authors: Jennifer Steele, Quanshun Zhang, Gillian Beamer, Michelle Butler, Terry Bowlin, Saul Tzipori

Institutions: Tufts University, Microbiotix (United States)

Language: English

Topic: Clostridium difficile and Clostridium perfringens research

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Institutes of Health, National Institute of Allergy and Infectious Diseases